'Triple negative' epithelial ovarian cancer and pathologic markers for prognosis

被引:5
作者
Liu, Naifu [1 ]
Wang, Xingwu [1 ]
Sheng, Xiugui [1 ]
机构
[1] Shandong Canc Hosp & Inst, Dept Gynecol Oncol, Jinan 250117, Shandong, Peoples R China
关键词
breast cancer; endometrial cancer; epithelial ovarian cancer; prognosis; targeted therapy; triple negative phenotype; METASTATIC BREAST-CANCER; PROGESTERONE-RECEPTOR; EXPRESSION; CARCINOMA; P53; EGFR; POLYMORPHISMS; BEVACIZUMAB; PHENOTYPE; ANDROGEN;
D O I
10.1097/GCO.0b013e32834252f5
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Purpose of review To summarize the recent evidence for 'triple negative' epithelial ovarian cancer (TNEOC), characterized by lack of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor type 2 (HER2), and to discuss its potential pathologic markers for prognosis and targeted therapy. Recent findings 'Triple negative' phenotype is traditionally referred to as a specific subtype of breast cancer negative for estrogen receptor, progesterone receptor and HER2 expression. Recent studies have shown that such 'triple negative' phenotype also exists in ovarian and endometrial cancer. TNEOC accounts for about 15% of epithelial ovarian carcinoma. This specific subtype tends to exhibit more aggressive characteristics and a worse prognosis. The molecular features of TNEOC are similar to those of 'triple negative' breast cancer (TNBC), a widely studied histological subtype. Recently, a panel of specific pathologic biomarkers has been identified in TNBC. Currently, phase I and phase II trials to examine the safety and efficacy of a poly (ADP-ribose) polymerase inhibitor (olaparib) and angiogenesis inhibitors (sunitinib and bevacizumab) in TNBC are ongoing. These TNBC-associated pathologic markers could be used to screen for novel prognostic factors and therapeutic targets in TNEOC. Summary 'Triple negative' phenotype has important implications for clinical management of patients with ovarian cancer.
引用
收藏
页码:19 / 23
页数:5
相关论文
共 37 条
[1]   Molecular Characterization of Breast Cancer with High-Resolution Oligonucleotide Comparative Genomic Hybridization Array [J].
Andre, Fabrice ;
Job, Bastien ;
Dessen, Philippe ;
Tordai, Attila ;
Michiels, Stefan ;
Liedtke, Cornelia ;
Richon, Catherine ;
Yan, Kai ;
Wang, Bailang ;
Vassal, Gilles ;
Delaloge, Suzette ;
Hortobagyi, Gabriel N. ;
Symmans, W. Fraser ;
Lazar, Vladimir ;
Pusztai, Lajos .
CLINICAL CANCER RESEARCH, 2009, 15 (02) :441-451
[2]   Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial [J].
Audeh, M. William ;
Carmichael, James ;
Penson, Richard T. ;
Friedlander, Michael ;
Powell, Bethan ;
Bell-McGuinn, Katherine M. ;
Scott, Clare ;
Weitzel, Jeffrey N. ;
Oaknin, Ana ;
Loman, Niklas ;
Lu, Karen ;
Schmutzler, Rita K. ;
Matulonis, Ursula ;
Wickens, Mark ;
Tutt, Andrew .
LANCET, 2010, 376 (9737) :245-251
[3]   Treatment of triple-negative metastatic breast cancer: toward individualized targeted treatments or chemosensitization? [J].
Berrada, N. ;
Delaloge, S. ;
Andre, F. .
ANNALS OF ONCOLOGY, 2010, 21 :30-35
[4]   Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research [J].
Bosch, Ana ;
Eroles, Pilar ;
Zaragoza, Rosa ;
Vina, Juan R. ;
Lluch, Ana .
CANCER TREATMENT REVIEWS, 2010, 36 (03) :206-215
[5]   TRIPLE NEGATIVE BREAST CANCER - CURRENT STATUS AND PROSPECTIVE TARGETED TREATMENT BASED ON HER1 (EGFR), TOP2A AND C-MYC GENE ASSESSMENT [J].
Bouchalova, Katerina ;
Cizkova, Magdalena ;
Cwiertka, Karel ;
Trojanec, Radek ;
Hajduch, Marian .
BIOMEDICAL PAPERS-OLOMOUC, 2009, 153 (01) :13-17
[6]  
Brustmann H, 2007, INT J GYNECOL PATHOL, V26, P147, DOI 10.1097/01.pgp.0000235064.93182.ec
[7]   Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane [J].
Burstein, Harold J. ;
Elias, Anthony D. ;
Rugo, Hope S. ;
Cobleigh, Melody A. ;
Wolff, Antonio C. ;
Eisenberg, Peter D. ;
Lehman, Mary ;
Adams, Bonne J. ;
Bello, Carlo L. ;
DePrimo, Samuel E. ;
Baum, Charles M. ;
Miller, Kathy D. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) :1810-1816
[8]   TBCRC 001: EGFR inhibition with cetuximab added to carboplatin in metastatic triple-negative (basal-like) breast cancer [J].
Carey, L. A. ;
Rugo, H. S. ;
Marcom, P. K. ;
Irvin, W., Jr. ;
Ferraro, M. ;
Burrows, E. ;
He, X. ;
Perou, C. M. ;
Winer, E. P. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[9]   Triple-negative breast cancer [J].
Chacon, Reinaldo D. ;
Costanzo, Maria V. .
BREAST CANCER RESEARCH, 2010, 12
[10]   Cyclooxygenase-2 (COX-2), epidermal growth factor receptor (EGFR), and Her-2/neu expression in ovarian cancer [J].
Ferrandina, G ;
Ranelletti, FO ;
Lauriola, L ;
Fanfani, F ;
Legge, F ;
Mottolese, M ;
Nicotra, MR ;
Natali, PG ;
Zakut, VH ;
Scambia, G .
GYNECOLOGIC ONCOLOGY, 2002, 85 (02) :305-310